Correction to: Biological Evaluation of Copper Complexes Derived from O- and N-, O-Donor Ligands

Pharmaceutical Chemistry Journal, Jan 2018

Muhammad Nadeem Akhtar, Muhammad Shahid, Masaaki Sadakiyo, Muhammad Ikram, Sadia Rehman, Irshad Ahmed

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs11094-018-1720-x.pdf

Correction to: Biological Evaluation of Copper Complexes Derived from O- and N-, O-Donor Ligands

The title should read: BIOLOGICAL EVALUATION OF COPPER COMPLEXES DERIVED FROM O- AND N-, O-DONOR LIGANDS The article submission date should read: Original article submitted May To the article “Biochemical Evaluation of Copper Compounds Derived from O- and N-/O- Donor Ligands,” by Muhammad Nadeem Akhtar, Muhammad Shahid, Masaaki Sadakiyo, Muhammad Ikram, Sadia Rehman, and Irshad Ahmed, Vol. 51, No. 4, pp. 272 - 276, July, 2017 The abstract should read: The complexes [CuII2(benz)4(Hbenz)2] (1) and [CuII(ppa)2(H2O)2]n (2), where benz = benzoate and ppa = 3-pyridinepropionic acid, were synthesized and studied for their 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity and inhibition of enzymes such as acetylcholinesterase (AChE), butyrylcholinesterase (BChE), lipoxygenase (LOX), urease, chymotrypsin, and -glucosidase. The synthesized complexes were also studied by the hemolytic method for their cytotoxicity and found to be low-toxicity substances. For AChE inhibition, complex 2 showed IC50 = 31.22 0.45 M compared to 1 with IC50 = 36.52 0.44 M. Both compounds showed comparably low activity against BChE and were also active against urease, but complex 1 exhibited selective anti-urease activity. The anti- -glucosidase activity of both complexes was comparable to that of the standard drug used. - valuable -glucosidase, AChE, and BChE inhibition, which indicates that these compounds can be potential candidates in drug development. In summary, we conclude that part of the current study can provide valuable leads in the treatment of AD. In addition, the present study paves the way for further investigations into copper complexes for effective treatment options in medicine and as therapeutic pharmaceuticals, etc. Reference 17(b) should read L. A . Borkowski and C. L. Cahill , Acta Crystallogr., E59 , m1127 - m1128 ( 2003 ). References 32 and 33 were inadvertently omitted and should read as follows: 32 . L. Zhang , S. B. Mulrooney , A. F. Leung , Y. Zeng , B. B. Ko , R. P. Hausinger , and H. Sun , Biometals, 19 ( 5 ), 503 - 511 ( 2006 ). 33. M. Ikram , S. Rehman , Faridoon, R. J. Baker , H. U. Rehman , A. Khan , M. I. Choudhary , and S.-Ur-Rehman, Thermochim. Acta, 555 , (...truncated)


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs11094-018-1720-x.pdf

Muhammad Nadeem Akhtar, Muhammad Shahid, Masaaki Sadakiyo, Muhammad Ikram, Sadia Rehman, Irshad Ahmed. Correction to: Biological Evaluation of Copper Complexes Derived from O- and N-, O-Donor Ligands, Pharmaceutical Chemistry Journal, 2018, pp. 1-2, DOI: 10.1007/s11094-018-1720-x